Shilpa Medicare Limited (SHILPAMED.BO)
Shilpa Medicare Limited operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Raichur, KA, IN. The stock last traded at $821.90, up 1.80% on the session, giving a market capitalisation of $80.37B. Its beta of 0.29 implies it has historically moved less than the broad market.
Shilpa Medicare Limited, including its associated entities, specializes in the production and global distribution of active pharmaceutical ingredients (APIs), chemical intermediates, and finished drug formulations, serving markets across India, the United States, Europe, and internationally. Its extensive product catalog features prominent oncology APIs such as capecitabine, gemcitabine hydrochloride, pemetrexed, axitinib, erlotinib hydrochloride, and irinotecan hydrochloride, alongside non-oncology APIs like ambroxol, tranexamic acid, and ursodeoxycholic acid. The company also develops innovative drug delivery systems, biotechnological products (including peptides), and specialty chemicals. Furthermore, Shilpa Medicare offers comprehensive contract manufacturing services for a diverse range of dosage forms, including tablets, capsules, liquid, lyophilized, and sterile dry powder injectables. Complementing its core pharmaceutical activities, the company also diversifies into wind energy generation. Established in 1987, Shilpa Medicare Limited maintains its corporate base in Raichur, India.
Shilpa Medicare Limited is most often compared with the following Healthcare names: